정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1304 | Recruiting | Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With CoronavirUS | Covid19 | Drug: IFN beta-1a Drug: Dexamethasone |
Phase 2 | Faron Pharmaceuticals Ltd | INDUSTRY | 140 | All | 18 Years | University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States Newton-Wellesley Hospital, Newton, Massachusetts, United States Vanderbilt University School of Medicine, Nashville, Tennessee, United States |
| 1303 | Recruiting | Humoral and Cellular Responses to Vaccination Against Coronavirus Disease 2019 (COVID-19) in the Very Elderly Living in Geriatric Institutions | Elderly People Institutionalized in Long-term Care Services | Biological: Blood test to describe the humoral and cellular response to vaccination BNT162b2 in the elderly | Not Applicable | Gerond'if | OTHER | 80 | All | 18 Years | Geriatric Department, Charles Foix hospital, Ivry-sur-Seine, IIe-de-France, France |
| 1302 | Completed | Hydrocortisone for COVID-19 and Severe Hypoxia | Hypoxia | Drug: Hydrocortisone Drug: Sodium Chloride 9mg/mL |
Phase 3 | Scandinavian Critical Care Trials Group, Rigshospitalet, Denmark, Copenhagen Trial Unit, Center for Clinical Intervention Research, University of Copenhagen, Aarhus University Hospital | OTHER | 30 | All | 18 Years | Aarhus University Hospital - Dept of Intensive care, Aarhus, Denmark Rigshospitalet, Copenhagen, Denmark Dept of Infectious diseases, Rigshospitalet, Copenhagen, Denmark Herlev Hospital - Dept. of Intensive Care, Herlev, Denmark North Zealand Hospital, Hillerød, Denmark Hvidovre Hospital - Dept of Infectious diseases, Hvidovre, Denmark Hvidovre Hospital - Dept of Intensive Care, Hvidovre, Denmark Hvidovre Hospital - Dept of Pulmonary Medicine, Hvidovre, Denmark Kolding Hospital, Kolding, Denmark Køge Hospital, Køge, Denmark Dept of Intensive Care, Odense University Hospital, Odense, Denmark Roskilde Hospital, Roskilde, Denmark Slagelse Hospital, Slagelse, Denmark Viborg Hospital, Viborg, Denmark |
| 1301 | Not yet recruiting | Hydrogen Therapy in Patients With Moderate Covid-19 | Covid-19 | Drug: Mixture 3,6% H2 in N2 (96.4%) | Phase 1 | University Hospital, Grenoble | OTHER | 10 | All | 18 Years | |
| 1300 | Recruiting | Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 | COVID-19 Prevention | Drug: Hydroxychloroquine (HCQ) Other: Standard care Other: Placebo |
Phase 3 | Postgraduate Institute of Medical Education and Research | OTHER_GOV | 1000 | All | 18 Years | Post Graduate Institute of Medical Education and Research, Chandigarh, India |
| 1299 | Withdrawn | Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients | COVID-19 | Drug: HCQ & AZ | Not Applicable | King Hussein Cancer Center | OTHER | 0 | All | 25 Years ~ 70 Years | King Hussein Cancer Center, Amman, Jordan |
| 1298 | Completed | Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection | COVID-19 | Drug: Hydroxychloroquine Drug: Ivermectin Drug: Placebo |
Phase 3 | Centenario Hospital Miguel Hidalgo | OTHER | 108 | All | 16 Years ~ 90 Years | Jose Manuel Arreola Guerra, Aguascalientes, Mexico |